IL122898A0 - Allergan -XCD32 fusion proteins - Google Patents

Allergan -XCD32 fusion proteins

Info

Publication number
IL122898A0
IL122898A0 IL12289896A IL12289896A IL122898A0 IL 122898 A0 IL122898 A0 IL 122898A0 IL 12289896 A IL12289896 A IL 12289896A IL 12289896 A IL12289896 A IL 12289896A IL 122898 A0 IL122898 A0 IL 122898A0
Authority
IL
Israel
Prior art keywords
xcd32
allergan
fusion proteins
fusion
proteins
Prior art date
Application number
IL12289896A
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL122898A0 publication Critical patent/IL122898A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Insects & Arthropods (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL12289896A 1995-08-16 1996-08-16 Allergan -XCD32 fusion proteins IL122898A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9516760.7A GB9516760D0 (en) 1995-08-16 1995-08-16 Organic compounds
PCT/EP1996/003616 WO1997007218A1 (en) 1995-08-16 1996-08-16 Allergen-xcd32 fusion proteins

Publications (1)

Publication Number Publication Date
IL122898A0 true IL122898A0 (en) 1998-08-16

Family

ID=10779307

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12289896A IL122898A0 (en) 1995-08-16 1996-08-16 Allergan -XCD32 fusion proteins

Country Status (16)

Country Link
EP (1) EP0846178A1 (en)
JP (1) JPH11513025A (en)
KR (1) KR19990036440A (en)
CN (1) CN1193353A (en)
AU (1) AU6873596A (en)
BR (1) BR9610239A (en)
CA (1) CA2227795A1 (en)
CZ (1) CZ43798A3 (en)
GB (1) GB9516760D0 (en)
HU (1) HUP9802349A3 (en)
IL (1) IL122898A0 (en)
NO (1) NO980566L (en)
PL (1) PL324897A1 (en)
SK (1) SK19398A3 (en)
TR (1) TR199800214T1 (en)
WO (1) WO1997007218A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9724531D0 (en) 1997-11-19 1998-01-21 Smithkline Biolog Novel compounds
AU750358B2 (en) 1997-12-02 2002-07-18 Medarex, Inc. Cells expressing anti-Fc receptor binding components
EP1221317A1 (en) * 2000-12-28 2002-07-10 SHAN-Beteiligungsgesellschaft m.b.H. Vaccines containing hybrid polypeptides consisting of at least two different allergenic proteins
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
BG65715B1 (en) * 2003-09-04 2009-08-31 Чавдар ВАСИЛЕВ Device for selective suppression of pathologic dna-specific b cells
BG65954B1 (en) * 2005-01-05 2010-07-30 Чавдар ВАСИЛЕВ Means for selective suppression of the activity of pathologic autoreactive b-cells
US9636415B2 (en) 2006-03-03 2017-05-02 S-Target Therapeutics Gmbh Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
EP1829895A1 (en) * 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
BR112014031327B1 (en) 2012-06-15 2022-02-01 Immunomic Therapeutics, Inc Nucleic acid molecules for the treatment of allergies
EP2872169B1 (en) 2012-07-13 2021-09-01 S-TARget therapeutics GmbH Immunoregulatory vaccine
US9005630B2 (en) 2012-11-01 2015-04-14 Veterinaerinstituttet Fusion proteins for the treatment of allergic diseases
DK2914285T3 (en) * 2012-11-01 2017-02-27 Veterinærinstituttet New fusion proteins for the treatment of allergic diseases
ES2665780T3 (en) 2013-05-21 2018-04-27 Tyg Oncology Ltd. Immunogenic composition of gastrin peptide
CN113186167B (en) * 2021-04-28 2021-11-30 中国食品药品检定研究院 Method for determining biological activity of anti-CD 20 monoclonal antibody drug ADCP

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024281A1 (en) * 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
WO1995032734A1 (en) * 1994-05-26 1995-12-07 Innogenetics N.V. New methods and compounds for the selective modulation of antigen-specific t-cell responsiveness

Also Published As

Publication number Publication date
CN1193353A (en) 1998-09-16
CZ43798A3 (en) 1998-06-17
BR9610239A (en) 1999-06-15
HUP9802349A3 (en) 1999-04-28
AU6873596A (en) 1997-03-12
KR19990036440A (en) 1999-05-25
NO980566D0 (en) 1998-02-10
CA2227795A1 (en) 1997-02-27
NO980566L (en) 1998-02-10
HUP9802349A2 (en) 1999-01-28
TR199800214T1 (en) 1998-06-22
SK19398A3 (en) 1998-09-09
PL324897A1 (en) 1998-06-22
GB9516760D0 (en) 1995-10-18
EP0846178A1 (en) 1998-06-10
WO1997007218A1 (en) 1997-02-27
JPH11513025A (en) 1999-11-09
MX9801253A (en) 1998-05-31

Similar Documents

Publication Publication Date Title
GB9718609D0 (en) Fusion protein
AU3827695A (en) Antigen-binding fusion proteins
AU4382193A (en) BPI-immunoglobulin fusion proteins
AU5065198A (en) Fusion proteins having increased half-lives
GB9525474D0 (en) Antifungal proteins
IL122898A0 (en) Allergan -XCD32 fusion proteins
GB9510830D0 (en) Proteins
GB9500601D0 (en) Modified peptides
ZA9710338B (en) Proteins
AU9798398A (en) Gfp-annexin fusion proteins
GB9314802D0 (en) Modified proteins
IL115317A0 (en) Proteins
AU5284296A (en) Immune-evading proteins
GB9413316D0 (en) Novel proteins
GB9519865D0 (en) Protein
AU6153396A (en) E6ap-binding proteins
GB9622436D0 (en) Protein
ZA934094B (en) BPI-immunoglobulin fusion proteins
GB9502138D0 (en) Proteins
GB9524341D0 (en) Proteins
GB9713150D0 (en) Fusion proteins
GB9509102D0 (en) Modified proteins
AUPM637594A0 (en) Novel fusion proteins
IL116044A0 (en) Chimeric proteins
GB9511729D0 (en) Protein